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the study population were discharged on beta blockers. During a mean follow-up of 67 
months (rangel- months) 602 deaths occurred in the study population. On multivari- 
ate analyses, patients discharged on antiarrhythmic medication had significantly higher 
mortality (hazard ratio 1.47, 95% Cl 1 .l l-l .97, p=O.O63) compared to those discharged 
on no drug therapy. Sub group analysis identtfied that the excess mortality was due to 
class Ill agents, Mortality in class I agents was no different than no drug therapy. Patients 
receiving beta-blockers had significantly less mortality (hazard ratio 0.44, 95% Cl 0.22- 
0.66, pcO.001) compared to those discharged on no beta blockade. In conclusion use of 
antiarrhythmic drugs may worsen long-term survival in the defibrillator populatton com- 
pared to no drug therapy. Use of beta-blockers was associated with significant survival 
advantage in this study. 
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Background: Treatment of congestive heart failure (CHF) aims for symptomatic relief 
and reduction of mortality. An implantable cardiovetter defibrillator (ICD) prevents sud- 
den death in patients at high risk, whereas recent data suggest that biventricular (BV) 
pacing in patients with CHF may improve functional status. The combination of these 2 
treatments rnav be svnarctistic. It is unknown. however. which percentaae of patients with 
Background: Dofetilide (DOF) is a relatively new antiarrhythmic agent utilized for the 
treatment of atnal fibnllation. Although it has been studied in patients (pts) with underly- 
ing heart disease and left ventricular dysfunction, little data is available regarding its use 
tn pts with tmplantable cardiovetter defibrillators (ICDs) and known ventricular tachycar- 
dia (VT). 
Methods: We examined follow-up on 17 ICD pts treated with DOF for atrial fibrillation. 
Results: Mean age was 71 +/- 8 yrs, with 14 men, and mean LVEF 30 +/- 11%. Coronary 
disease was present in 12 pts and a nonischemic dilated cardiomyopathy in 5 pts. Indica- 
tions for ICD implantation include sustained VT or cardiac arrest in 10 pts. syncope in 6 
pts. and asymptomatic nonsustained VT with inducible VT in 1 pt. A history of congestive 
heart failure was noted in 12117 (71%) pts. Dosing was based on creatinine clearance 
and adjustments ware made based on the QT interval, as recommended by the mand- 
facturer. The defibrillation threshold (DFT) was 14.6 +/- 4.9 joules at baseline and 11 .l +I 
- 3.8 joules at follow-up on dofetilide (p=O.O7). The mean dofetilide dose was 662 +/- 305 
mcg/day. Mean follow-up was 209 +i- 202 days (median 82 days), and 9/17 (53%) 
remain in sinus rhythm on DOF. DOF was discontinued in 6 pts due to inefficacy, in 1 pt 
due to noncompliance, and in 1 pt due to nausea and a creatinine of 2.6. NO proarrhyth- 
mia was noted, and there were no drug-related deaths. 
Conclusions: DOF is well-tolerated and appears to be effective for the treatment of atrial 
fibrillation in ICD pts with underlying heart disease in short-term follow-up. Despite the 
preexisting history of ventricular arrhythmias, no adverse ventricular arrhythmias were 
noted in thus small group of pts. In addition, no detrimental effects on the DFT were 
noted. DOF may serve as an effective alternative to amiodarone in this pt population with 
less risk of end organ toxicity. 
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an ICD indication are potential candidates for BV pacing. 
Methods: All natients who received an ICD were analvzed for eliaibilitv of BV bacind 
Based on the available literature, established critena for BV pacing included NYHA class 
Ill or IV (z- 6 months) and a QRS duration z.120 ms. Patients in NYHA class II with a left 
ventricular ejection fraction (LVEF) ~30% and QRS z-120 ms were also considered eligt- 
ble. The incidence of potential exclusion criteria, including atrial fibrillation (AF), RBBB 
and PR interval ~150 ms, was also assessed. 
Results: 390 consecutive patients received an ICD from June 1996 till March 2001 at 
our hospital. There were 315 men and 75 women (mean age of 58 * 17 years). Underly- 
ing cardiac disease was ischemic hear-l disease (n=281, 72%) idiopathic dilated cardi- 
omyopathy (CM) (n=51, 13%) primary CM (n=31, ES), and miscellaneous in 7% (n=27) 
of the patients. Indications for ICD implantation were out hospital cardiac arrest (n=l99, 
51%). ventricular tachyarrhythmia (n=l72, 44%) and preventive (n=l9, 5%). In the 390 
patients the mean LVEF was 34 f 25%. The incidence of severe CHF (NYHA class III/IV) 
was 19% (74 pattents); 62 (16%) patients were in NYHA class II with an LVEF <30%. of 
these 136 patients, 70 had a QRS duration >120 ms (42 LBBB, 14 RBBB, 14 intraventric- 
ular conduction delay). Thus, a total of 70 (18%) patients ware eligtble for BV pacing in 
addition to an ICD. When patients either tn chronic AF or with RBBB were excluded, this 
number was reduced to 48 (12%). None of the patients had a PR tnterval<l50 ms (mean 
196 * 31ms, range 155 - 265). 
Conclusion: 12.18% of patients with an ICD indication are potential candidates for BV 
pacing. Screening for eltgtbtltty of BV pacing should be routinely considered in patients 
with CHF scheduled for ICD implantation. 
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Background: Recent studies have demonstrated the value of biventricular pacing (biVP) 
in patients with CHF, diminished ejection fraction (EF), and left bundle branch block. 
These patients commonly have antiarrhythmic drug-resistant atrial fibrillation (DRAF). 
Optimal management may include atrial rhythm control. Previous studies in DRAF 
patients with preserved EF have demonstrated excellent long-term atrial rhythm control 
utilizing an atrial arrhythmia management device (AAMD). We hypothesized that an 
AAMD adapted to provtde btVP would be feasible and safe in carefully selected patients. 
Methods: In 20 patients with class II-IV CHF, EF<35%. left bundle branch block and 
DRAF with controlled ventncular response (16 men, ages 42-80 years. CAD in 13) an 
AAMD (Medtronic model 7250 [n=2] or 7276 [n=lE]) was implanted, coupled to right 
atrial appendage, right ventrtcular apical, and left venticular (epicardial [n=2]; trans- 
vents [n=lEt]) leads. For pactng and sensing, the ventricular leads were married by an 
adaptor (Medtrontc model 2872). Bradycardia programmtng was DDD or DDDR, with AV 
delays optimtzed ustng echocardrography. Ventricular tachyarrhythmia (VT) program- 
ming was stngle zone (median VT detection interval 280 msec). AF programming 
included “preventton pacing,” antitachycardia pacing, and patient-commanded shock. 
Previously inefficacious antiarrhythmic drug therapy was utilized as needed as an adju- 
vant rn patients to reduce AF burden. Results There were no implant complications. 
Durtng a followup interval ranging from 41 to 580 days, 7 patients have had AF events 
treated by the dewce; 5 patients have elicited shock, all without complication. Three 
patients are taking an anttarrhythmic drug. Two patients have undergone AV node abla- 
tion for uncontrollable AF burden. Single automatic shocks for device-perceived VT have 
been deftvered in 2 patients (one due to double- counted slow VT, the other due to elec- 
tromagnetic interference). Improvement of one or more HF class has been observed in 
13 patients; the remainder are unchanged. Conclusion: In selected patients, the cod- 
pling of an AAMD and biVP is feasible. In future systems, “srngle chamber” ventricular 
sensing is mandatory 
1064-20 Reliability and Clinical Benefits of a New Subthreshold 
Noninvasive Shock Lead Integrity Test 
Andreas Schuchert, Jochen Winter, Thomas Meinertz, Ludwig Binner, on behalf of the 
Reliance Investigators, University Hospital Hamburg-Eppendorf. Hamburg, Germany, 
Heine University, Diisseldorf, Germany 
Background: The integrity of the defibrillation lead is crucial for the proper function of 
implanted cardioverter / Uefibrillators. Serial measurements of the shock lead impedance 
are the most reliable non-invasive method to verify the integrity. The current approach is 
to deliver an at least 1 -J shock. As this is painful for the patient, deep sedation is manda- 
tory. The aim of the prospective study was to compare a new subthreshold measurement 
for shock lead impedance with the standard measurement. 
Methods: The study included 123 patients who received in 25 European centers either a 
Prism DR (n=73) or VR (n=50. Guidant. St. Paul, MN, USA) defibrillator. The deftbrillator 
was connected to the single coil (models 012710128; n = 39) or dual coil (models 0147/ 
0148; n = 84) Endotak Reliance defibrillation lead. The defibrillator delivers for the shock 
lead integrity test a cl mJ subthreshold pulse through the single coil or dual coil lead and 
the defibrillator housing (can). The current density of the test pulse is l/lOOth of a pacing 
pulse. Non-invasive shock lead impedance was measured for the defibrillation vectors 
from the distal coil to the proximal coil and can as well as from the distal coil to the can. 
The standard measurement for shock lead impedance was with a 17J shock. 
Results: The shock lead impedance for the vector from the distal coil to the proximal coil 
and the can was 42 * 5 ohms (95% confidence interval (Cl): 41 44 ohms) with the lead 
integrity test and and 41 * 4 ohms (*95% Cl: 39 43 ohms) with a high-energy shock (p 
= O.lS).The shock lead impedance for the vector from the distal coil to the can was 63 f. 
7 ohms (*95% Cl: 60 - 66) with the lead integrity test and 60 * 8 ohms (295% Cl: 56 - 64 
ohms) with a high-energy shock (p = 0.44). The vector from the distal coil to the can had 
a significant higher shock lead impedance than from the distal coil to the proximal coil 
and the can (p=O.OOl). 
Conclusion: The new subthreshold shock lead integrity test measured shock lead imped- 
ance similar to the standard measurement with the delivery of the high-energy shock. 
This non-invasive test is a useful diagnostic method as it allows serial measurements of 
the shock lead impedance during follow-up without the need for sedation. 
